GILEAD SCIENCES, LDA secures contract for General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 2024/0900- ELVITEGRAVIR COBICISTATE EMTRICITABINA TENOFOVIR ALAFENAMIDA [150 150 200 10 MG; CAP/COMP]

Posted On: 2025-08-19

Portugal, Aug. 19 -- Portugal based GILEAD SCIENCES, LDA has secured contract from Unidade Local de Saude Santa Maria, E.P.E. for General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 2024/0900- ELVITEGRAVIR COBICISTATE EMTRICITABINA TENOFOVIR ALAFENAMIDA [150 150 200 10 MG; CAP/COMP]. The value of the contract is worth 5093400 EUR.

Published by HT Digital Content Services with permission from Pivotal Sources....

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

GILEAD SCIENCES, LDA secures contract for General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents - 2024/0900- ELVITEGRAVIR COBICISTATE EMTRICITABINA TENOFOVIR ALAFENAMIDA [150 150 200 10 MG; CAP/COMP]